1. Patz A. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984; 98:374–5.
Article
2. Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology. 2007; 114:520–4.
3. Mitchell P, Smith W, Chang A. Prevalence and associations of reti-nal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996; 114:1243–7.
Article
4. Greer DV, Constable IJ, Cooper RL. Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol. 1980; 8:207–9.
Article
5. Channa R, Smith M, Campochiaro PA. Treatment of macular ede-ma due to retinal vein occlusions. Clin Ophthalmol. 2011; 5:705–13.
6. Ryan SJ, Oick SB, Jampol LH, Haller JA. Retina. 3rd ed,. St. Louis: Mosby Co;2001. p. chap. 55–7.
7. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480–7.
Article
8. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of in-creased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002; 120:1644–50.
Article
9. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the ef-fect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009; 50:1025–32.
Article
10. Pe'er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998; 105:412–6.
11. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008; 92:518–22.
Article
12. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bev-acizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007; 27:419–25.
Article
13. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for mac-ular edema following branch retinal vein occlusion: six-month pri-mary end point results of a phase III study. Ophthalmology. 2010; 117:1102–12.e1.
14. The Branch Vein Occlusion Study Group. Argon laser photo-coagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984; 98:271–82.
15. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-con-trolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010; 117:1134–46.e3.
Article
16. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intra-vitreous injection: a comprehensive review. Retina. 2004; 24:676–98.
Article
17. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacoki-netics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008; 146:508–12.
Article
18. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina. 2007; 27:1196–200.
Article
19. Song IJ, Kim HW, Yun IH. Long-term effects of intravitreal bev-acizumab injection for macular edema secondary to branch retinal vein occlusion. J Korean Ophthalmol Soc. 2012; 53:283–90.
Article
20. Magargal LE, Kimmel AS, Sanborn GE, Annesley WH Jr. Temporal branch retinal vein obstruction: a review. Ophthalmic Surg. 1986; 17:240–6.
Article
21. Stefánsson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001; 79:435–40.
22. Larsson J, Bauer B, Andréasson S. The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion. Acta Ophthalmol Scand. 2000; 78:187–90.
Article
23. Kim YG, Kim ES, Kim MS, et al. Early and late intravitreal bev-acizumab injection in macular edema due to branch retinal vein occlusion. J Korean Ophthalmol Soc. 2009; 50:1527–30.
Article
24. Song YB, Park SP. Short-term effects of intravitreal bevacizumab injection and macular edema patterns in branch retinal vein occlusion. J Korean Ophthalmol Soc. 2010; 51:379–85.
Article
25. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained bene-fits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011; 118:1594–602.
Article